Jared Whitlock


Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Robotic Surgery Rides Tech Momentum Wave

MEDICINE: High Volume a Must; Adoption Becoming Norm

In San Diego hospitals, robots are on the rise, judging by splashy marketing and an increase in robotic surgery cases, per data obtained by the San Diego Business Journal.

Tease photo

Ionis Pharmaceuticals Hires New Chief Business Officer

Damien McDevitt has joined Carlsbad’s Ionis Pharmaceuticals as chief business officer.

UC San Diego Launches Center to Spark Anti-Parasitic Drugs

A new UC San Diego center is targeting an unmet need: parasitic infections hurting poor and underserved communities.

Co. Creates, Facilitates CRO Marketplace

PHARMA: Scientist.com Doubles Revenue to $50M

Scientist.com reported $50.27 million in 2017 revenue, a whopping increase from $23.07 million in 2016 and $6 million in 2015.

Tease photo

Senomyx Shareholder Calls for Sale of Co., Chair Resignation

A shareholder of San Diego-based biotech Senomyx is pushing for the company’s chairman to resign, an immediate company sale and a new board seat.

Alzheimer’s Association Awards $175,000 Fellowship to UC San Diego Researcher

The San Diego/Imperial Chapter of the Alzheimer’s Association awarded a three-year, $175,000 fellowship to a UC San Diego researcher on a quest to determine the earliest indications of Alzheimer’s disease.

China’s CROs Make Connection in S.D.

PHARMA: They’re Part of Growing Biotech Relationship

In San Diego, the last decade gave rise to biotechs farming out work to contract research organizations, or CROs. It’s an industry increasingly colored by China.

Metacrine Raises $65 Million in Series C Round

San Diego biotech Metacrine, which is working on drugs for liver, metabolic and gastrointestinal diseases, last week closed a $65 million Series C round.

Trovagene Closes $18M Public Offering

San Diego biotech Trovagene closed an $18 million public offering on June 12.

Salk Researcher Resigns After Investigation

A well-known researcher at Salk Institute for Biological Studies resigned on June 11 after an investigation into his conduct.

Vical Pulls Plug on Herpes Vaccine Program

San Diego-based Vical is terminating its herpes vaccine candidate following not-so-great mid-stage clinical trial results.

ResMed Acquisition to Deliver on Home Care

HEALTH: Brings Opportunities in Billing, Records and Analytics

ResMed’s acquisition of Healthcarefirst looks to tap into a growing trend: digitally connected devices for those who prefer medical care at home.

Tease photo

Artemis Makes Patients Priority in Clinical Trials

MEDICINE: Diversity Is a Must, Both in Patients and Studies

Artemis Institute for Clinical Research helps to advance groundbreaking treatments. A challenge in this line of work: getting people in the door.

Tease photo

Oska Wellness Hires New COO/CFO

A COO/CFO gig at Carlsbad’s Oska Wellness belongs to Bob Ohlweiler, who has held positions with Hewlett-Packard, Kodak, Yahoo!, Razer, and MusicMatch.

Venter Exits CEO Role

Craig Venter is retiring as the CEO of San Diego-based Human Longevity Inc., about five months after reassuming the role.

Pfenex Raises $39.4 Million in Stock Offering

Net proceeds from Pfenex’s common stock offering amounted to $39.4 million, it was recently announced.

Biocom Appoints Four Board Members

San Diego-based trade group Biocom appointed four new board members. The new members, announced May 31, play major roles in the region’s life sciences ecosystem:

ResMed to Acquire HEALTHCAREfirst

San Diego-based ResMed will acquire HEALTHCAREfirst, which specializes in software for home health and hospice agencies.

Payne Back in Charge at Arcturus Therapeutics

Once-ousted CEO Joseph Payne is back leading Arcturus Therapeutics. Even he saw a return as a longshot.

New Chair, Board Member for California Life Sciences Association

The California Life Sciences Association has a new board member: Jared Watkin, the senior vice president of Diabetes Care at Abbott Laboratories.

Arcturus, Former CEO Reach Settlement

Former Arcturus CEO Joseph Payne appears to have prevailed in a fight for control of the company.

Biotechs Seek Reward Of Commercialization

PHARMA: Skipping Partnerships Can Build Profits and Skill Sets

Several San Diego biotechs — including Neurocrine and Arena Pharmaceuticals — are bucking the norm by handling drug commercialization themselves.

Tease photo

J. Craig Venter Retiring from Human Longevity

J. Craig Venter is retiring as the CEO of San Diego-based Human Longevity, Inc., about five months after reassuming the role.

Local Cos. Find Rich Vein to Tap in Blood Diagnostics

BIOTECH: From Cancer to Concussions, Efforts Change Cost, Course of Treatments

Banyan Biomarkers hit a milestone in February when its blood test for traumatic brain injuries won U.S. Food and Drug Administration approval.

Tease photo

ResMed Disputes Australia Tax Levy of $190.1M

FINANCE: Co. Doesn’t Expect Any Change to U.S. Tax Assessment

San Diego-based ResMed is challenging an Australian Taxation Office assessment saying the company owes $190.1 million.

Tease photo

Arcturus Proxy Fight Set for June 25

A proxy fight between Arcturus Therapeutics’ board and former CEO will play out at a newly set June meeting.

Bloom Science, Focused on Epilepsy Treatments, Debuts

San Diego-based Bloom Science, which emerged May 24, is drawing upon gut bacteria to develop medicines.

Evofem Lists $39.9M Public Stock Offering

San Diego biotech Evofem Biosciences, which focuses on women’s sexual and reproductive health, announced a public stock offering on May 22.

AristaMD Hires Chief Strategy Officer

San Diego’s AristaMD has hired Adam Darkins, known for his work with the Department of Veterans Affairs, as the company's chief strategy officer.

La Jolla Emergency Department Receives First-of-Its-Kind Geriatric Accreditation

The Gary and Mary West Emergency Department at UC San Diego Health last week was accredited as a geriatric emergency department, the first such accreditation in California and one of only eight nationally.

Cidara Therapeutics, Rutgers University Receive $5.5 Million Grant

San Diego-based Cidara Therapeutics and Rutgers University were awarded a $5.5 million grant to research and further develop an immunotherapy platform.

Cannabis Medicine Moves Toward Likely FDA OK

HEALTH: Drug Treats Seizures; Co. Prepares For Commercialization

A plant-derived cannabis medicine is poised to be the first of its kind to win U.S. Food and Drug Administration approval. A winner of the expected greenlight: Carlsbad’s Greenwich Biosciences.

Arena Quietly Returns With Promising Autoimmune Trials

PHARMA: Co. Transforms After Weight-Loss Flop

Arena Pharmaceuticals’ weight-loss drug flopped a few years ago, signaling a bleak future. That is, if you ignored Arena’s shelved compounds.

Tease photo

Accelerator Life Science Partners Opens San Diego Office

Accelerator Life Science Partners, a life science investment and management firm, has opened a San Diego office at The Alexandria at Torrey Pines.

Sherry Lansing Joins The Scripps Research Institute Board

Former film executive Sherry Lansing, who led Paramount and Fox motion picture studios, has been named to The Scripps Research Institute board.

Edico Brings Valuable Tech Tools to Illumina

BIOTECH: Acquisition Moves Co. Toward Push-Button Process for Analysis

Illumina bought data processing specialist Edico Genome for $100 million as part of a bid to expand genomics testing in research and health care.

Tease photo

Illumina Buys Edico Genome for $100M

Genomics giant Illumina has purchased Edico Genome, adding a processing platform to Illumina’s portfolio.

MEI Pharma Reports $75 Million Private Placement

San Diego-based MEI Pharma reported on May 14 raising $75 million through a private placement, led by Vivo Capital and CAM Capital.

Cidara Reports Q1 Results

San Diego biotech Cidara Therapeutics reported a net loss of $16.7 million in the first quarter, compared to a $13.14 million net loss in the first quarter of last year.

Ionis’ New Role Is Managing Success

PHARMA: Partnerships and Promising Pipeline Boost Co.

When Stanley Crooke formed Ionis Pharmaceuticals in 1989, he saw the venture as a longshot. He told investors as much.

Tease photo

Escient Pharmaceuticals Snags $40M Series A Round

San Diego-based Escient Pharmaceuticals launched with a $40 million Series A round, which will go toward a pipeline of novel drugs.

Neurana Pharmaceuticals Raises $60 Million in Series A Round

San Diego-based Neurana Pharmaceuticals raised $60 million in Series A financing for a relaxant that treats acute, painful muscle spasms.

Luna DNA Raises $2 Million in New Investment Round

Solana Beach-based Luna DNA raised $2 million in a new round of funding, led by Illumina Ventures and Arch Venture Partners, it was announced May 8.

Veteran Leaders, Past Successes Play Part In Record VC Investment

FINANCE: Q1 Delivers Record Investment Locally and Nationally

Investment in San Diego-based life sciences companies hit a record high $417.9 million in quarter one of 2018, according to an April CBRE Group Inc. report.

Tease photo

Scripps Translational Science Institute Awarded $34 Million

The Scripps Translational Science Institute (STSI) was awarded $34 million in renewed funding to advance genomic and digital technologies in clinical care.

AMN Healthcare Reports Q1 Results

AMN Healthcare reported $522 million in quarter one revenue, up 6 percent year over year, fueled by higher-than-expected staffing needs.

In China, Biotechs Take Partnership Path

TRADE: S.D. Cos. Able to Avoid Some of the Complexities

San Diego biotechs are inking deals with Chinese firms to tap into China’s ever-growing demand for groundbreaking drugs.

Tease photo

Q1: Dexcom Revenue Jumps 30%

San Diego-based Dexcom reported a 30 percent year-over-year revenue increase in quarter one results due a sharp increase in international sales.

NuVasive Reports Q1 Results

NuVasive reported $260.5 million in quarter one results, a 4.6 percent year-over year increase, with its core U.S. hardware business showing solid growth.

Synthorx Raises $63 Million in Series C Round

San Diego-based Synthorx — formed around synthetic biology for novel protein therapies — raised $63 million in a Series C round.